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ACE gene polymorphism and IgA nephropathy: An ethnically National registries of renal biopsies and epidemiologi-
homogeneous study and a meta-analysis. cal studies have shown IgA nephropathy (IgAN) as the
Background. Conflicting results have implicated the angio- most common form of primary glomerulonephritis in thetensin-converting enzyme (ACE) D allele in the progression
world [1–5]. In addition, some national and internationalof renal damage in patients with IgA nephropathy (IgAN). Most
registries of end-stage renal disease (ESRD) patientsof these findings have been obtained by heterogeneous studies.
Methods. We investigated the ACE insertion/deletion (I/D) receiving renal replacement therapy have shown IgAN
gene polymorphism by polymerase chain reaction (PCR) am- as the most common biopsy-proven primary glomerulo-
plification of genomic DNA in an ethnically homogenous sam- nephritis leading to ESRD [6–10]. Poor prognostic fac-ple size of IgAN patients from Southern Italy. The association
tors responsible for the progression of renal damage inbetween ACE I/D gene polymorphism and the development
these patients are male gender, older age, presence ofof the disease was examined in 247 biopsy-proven IgAN pa-
tients and 205 healthy subjects. The association with the pro- hypertension, moderate or severe proteinuria, and se-
gression of renal damage was evaluated in 136 patients with a vere renal lesions [11, 12]. It has been reported that
follow-up of 3 years according to the slope of the creatinine growth factors such as platelet-derived growth factor andclearance against time, and in 221 patients with a follow-up of
cytokines are responsible for the increased production1 year assessing by univariate and multivariate analyses of
of extracellular matrix contributing to the developmentrenal survival. These associations were further estimated in a
meta-analysis of seven studies retrieved in the Medline data- of glomerular sclerosis [13]. Angiotensin II modulates
base. The meta-analysis was performed according to the Man- the local production of these mediators and consequently
tel-Haenszel-Peto method when homogeneity of the studies
induces mesangial cell proliferation, mesangial matrixwas established using the 2 test by Breslow-Day.
production and progression of renal lesions [14].Results. No difference in the ACE I/D gene distribution be-
Angiotensin-converting enzyme (ACE) is a carboxyltween patients and controls and between patients with stable
and those with deteriorating renal function was found in our terminal dipeptidyl exopeptidase that converts angioten-
study. A meta-analysis performed separately for Caucasian and sin I to angiotensin II in the renin-angiotensin system.
Asian studies showed that the ACE I/D gene polymorphism
Angiotensin II is active in the circulating blood and localdid not contribute to the genetic susceptibility of the develop-
tissues [14]. Its production is modulated by the ACEment of IgAN (total OR 0.93, 95% CI, 0.71 to 1.23; and 0.95,
95% CI, 0.64 to 1.42, respectively) or the progression of the gene, which consists of 26 exons, and its locus is at chro-
renal damage (total OR 1.12, 95% CI, 0.67 to 1.88; and 2.26, mosome 17q23 [15, 16]. A 287 bp fragment identifies a
95% CI, 0.75 to 6.79, respectively) in both groups. polymorphism within the intron 16 of this gene and its
Conclusions. Our study and meta-analysis suggest caution in
insertion/deletion (I/D) defines the three genotypes: DDthe interpretation of results from association studies enrolling
and II homozygotes and ID heterozygote [17, 18]. Highheterogeneous populations. Further studies using new tests,
which are free of the bias due to population stratification and values of serum ACE activity have been found in subjects
ethnicity, are warranted. with the D allele [19], and Yoshida et al were first to
describe the high frequency of the DD genotype in IgAN
patients with progressive deterioration of renal function
Key words: angiotensin-converting enzyme gene, end-stage renal dis-
[20]. Subsequent contributions have produced conflictingease, RAS gene polymorphisms, progressive renal disease, primary
glomerulonephritis. results [21–26]. To date, the role of ACE I/D polymor-
phism in the development and progression of IgAN is
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pared our data with those of other investigators. Since (decrease 3 mL/min/year defined a deteriorating renal
function). Only patients with follow-up greater thanseveral studies have investigated this same question, a
meta-analysis of them was performed to provide a more three years and normal renal function at the time of renal
biopsy (serum creatinine value less than 1.5 mg/dL and/orreliable assessment of the significance of the association.
glomerular filtration rate higher than 70 mL/min) were
included in the analysis [27]. Second, renal survival was
METHODS
assessed in 221 patients with a follow-up of more than
Study patients and controls one year from the time of renal biopsy. The end point
was ESRD treated by dialysis or renal transplantation.Two hundred and seventy IgAN Caucasian patients
were diagnosed by renal biopsy in our division from Caucasian staff members and blood donors living in
Southern Italy (140 males and 65 females, mean age 33January 1986 to January 1999. Of them, a cohort of 247
patients (176 males and 71 females, mean age of 30  11 years) without a history of renal disease or renal failure
and with routinely negative urinalysis, matched for age12 years) who were living in Southern Italy and had
visited our out-patient facility in the last three years were and sex with IgAN patients, represented the control group.
included in the study. Diagnosis of IgAN was based
Extraction of genomic DNA andon the presence of IgA as the sole, predominant, or
genotype determinationscodominant immunoglobulin in the mesangial area of
glomeruli, without systemic disease (such as Scho¨nlein- Genomic DNA was isolated from 2.4 mL of ethylene-
diaminetetraacetic acid (EDTA) whole blood with a kitHenoch purpura, systemic lupus erythematosus) and
liver cirrhosis. The clinical picture was characterized by (Genomix; Talent SRL, Trieste, Italy). Polymerase chain
reaction (PCR) amplification to detect the ACE I/D poly-relapses of macrohematuria following infections of the
upper respiratory tract, and fever or persistent micro- morphism was carried out on 250 ng genomic DNA using
the published primers: 5-CTG GAG ACC ACT CCChematuria with or without proteinuria. The severity of
renal lesions was graded according to Lee’s classification ATC CTT TCT-3 and 5-GAT GTG GCC ATC ACA
TTC GTC AGA T-3 [17, 18]. Amplification with this[27]: grades 1 and 2  mild renal lesions; grade 3 
moderate lesions; grades 4 and 5  severe renal lesions. primer pair produced approximately 490 and 190 bp frag-
ments corresponding to the I and D alleles, respectively.No patient had received corticosteroid or immunosup-
pressive therapy in the two months prior to the study. In this reaction, a preferential amplification of the D allele
and inefficiency in amplification of the I allele could gener-One hundred and thirty-six patients had a follow-up of
three or more years, while 221 had a follow-up of one or ate mistyping of the ID heterozygote as a DD homozy-
gote [29]. For this reason, all samples found to be DDmore years; the total mean follow-up was 5.3  5.2 years.
Blood samples were obtained from all patients after after amplification with the conventional primers were re-
amplified using primer pair recognized insertion-specificappropriate informed consent. All patients had serial
measurements of serum creatinine, proteinuria, and sequences: 5-TGG GAC CAC AGC GCC CGC CAC
TAC-3 and 5-TCG CCA GCC CTC CCA TGC CCAblood pressure. The serum creatinine concentration was
determined by an autoanalyzer technique, using the TAA-3. Only the I allele produced a 335 bp amplicon.
The rate of false positives was 10% of the samples, whichmodified Jaffe method. Creatinine clearance (CCr) was
calculated by using the Cockcroft formula. Urine protein is similar to that found by other investigators [20, 25].
Angiotensinogen gene polymorphism (AGT M235T)concentration was measured by the pirogallolo method.
Proteinuria was classified as mild (1 g/day), moderate was examined by a mutagenically separated PCR tech-
nique (MS-PCR) based on a three-primer one-step assay(1 to 3 g/day) and severe (3 g/day). The persistence
of maximal level of proteinuria was considered for at (M235T1, 5-CCA GGG TGC TGT CCA CAC TGG
CTC CGG-3; M235T2, 5-AAG TGG ACG TAG GTGleast six months during the follow-up period. Proteinuric
patients were considered responsive to ACE inhibitors TTG AAA GGG AGG GTG CTG TCC ACA CTG
GCT TCC-3; M235T3, 5-TGT GGT CCT CCC ACGtherapy when a reduction of at least 50% of the baseline
proteinuria was obtained. Hypertension was defined as CTC TCT TGG-3), as previously designed [30].
Amplification with primer M235T1 and primer M235T3systolic blood pressure higher than 140 mm Hg and dia-
stolic blood pressure higher than 90 mm Hg. Hyperten- yielded a 134 bp product representing the 235T allele,
whereas amplification with primer M235T2 and primersive patients were considered responsive to antihyper-
tensive therapy when a reduction of blood pressure M235T3 yielded a 156 bp product, representing the M235
allele.below 140 to 90 mm Hg was obtained.
Two outcome measures of renal disease progression
Statistical analysiswere made in our population study. First, progression of
the renal damage was evaluated in 136 patients according Allelic frequency was deduced from the genotype dis-
tribution. Analysis was performed by the 2 test on theto the slope of the creatinine clearance against the time
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distribution of ACE D/I genotype and allele frequencies sessed on the basis of the 2 test by Breslow-Day using
between IgAN patients and controls, and between stable a significance level of P 0.05. Given the different allele
renal function and deteriorating renal function in IgAN frequencies reported for healthy controls, separate anal-
patients. Linear regression analysis was performed to yses were performed for Caucasians and Asians.
generate the rate of deterioration of CCr over time. Uni-
variate analysis of the renal survival was performed using
the Kaplan-Meier technique for censored data. The in- RESULTS
fluence of prognostic factors was assessed by univariate Population study
(log-rank test) and multivariate analyses (Cox’s propor-
In our cohort of 247 IgAN patients, we studied thetional hazard methods). For the statistical analysis, we
influence of the ACE genotype on the development ofused the StatView 5.0 program (1992 to 1998; SAS Insti-
IgAN and the progression of renal disease. With regardstute Inc., Cary, NC, USA).
to the development of disease, Table 1 shows the distri-A meta-analysis of ACE genotype polymorphism stud-
bution of the ACE genotypes and alleles in our IgANies in the development and progression of IgAN was per-
patient population at the time of renal biopsy. The ACEformed using studies identified by the Medline database
I/D genotype did not correlate with age (2  0.63; P literature research feature from the publication of the
first study [20] to May 1999. Abstracts, letters, and review 0.73) or gender (2  4.19, P  0.12), and did not influ-
articles were not considered for this analysis. All seven ence the presence of hypertension (2  3.29, P  0.14),
retrieved articles were critically assessed for their meth- the amount of daily proteinuria (2  3.42, P  0.49),
odological quality, with particular attention to the possi- abnormal renal function (2  1.1, P  0.58), or severity
bility of bias in the selection of cases (biopsy-proven of renal lesions (2  3.87, P  0.42). With regards to
IgAN) and controls; clinical characteristics such as the de- the progression of renal disease, we studied the distribu-
gree of proteinuria, blood pressure control and therapy; tion of the ACE genotypes and alleles in 136 IgAN
definition of progression of renal damage; and type of patient population with a follow up3 years. At the last
statistical analyses. Each article was evaluated indepen- follow-up, the ACE I/D genotype did not influence blood
dently by three investigators (two of whom were blinded pressure (2  0.10, P 0.95) and persistent proteinuria
to the name of the journal and the authors of the article)
(2 1.77, P 0.41). The ACE I/D genotype distributionusing a scoring sheet to list those elements important for
was identical in proteinuric IgAN patients responsivea meta-analysis [31]. The meta-analysis was performed
and not responsive to therapy with ACE-inhibitors (2according to the Peto method in which a 2  2 table
0.87, P  0.65) and in hypertensive patients responsivewas constructed for each candidate study [32]. This is a
and not responsive to other antihypertensive drugs (2modification of the Mantel-Haenszel method; by a sim-
0.69, P  0.71). The ACE I/D genotype distributionple set of operations, it allows weighted analyses for each
was not different between 99 patients with stable renalstudy based on calculation of its inverse variance. In meta-
function (average CCr slope, 0.2  3.1) and 37 patientsanalysis graphical representation, the area of the black
with deteriorating renal function (average CCr slope,square indicates the amount of information contributed
by each individual study and is inversely proportional to 	9.1 6.2; 2  4.23, P  0.12).
the standard error of the log of the odds ratio (OR). The ten-year cumulative renal survival rate for cen-
The main outcome measures of the meta-analysis were sored data (Kaplan-Meier) in 221 patients with a follow
the development of IgAN and the deterioration of renal up 1 year was 73%; 46 patients reached the end point
function, including the ESRD treated by dialysis or renal of ESRD.
transplantation. Progression of renal damage was de- Univariate analysis of survival curves (log-rank test)
fined as a decrease of renal function estimated by slope showed that serum creatinine (P
 0.0001), daily protein-
of creatinine clearance against time [20, 26], slope of the uria (P 
 0.0001), histological grade (P 
 0.0001), and
reciprocal of serum creatinine [21], increase of initial blood pressure (P 
 0.0001) were correlated with poor
serum creatinine to a mean of 4.5  0.86 mg/dL [25],
renal survival. Gender, age, and the AGT M235T andand occurrence of ESRD [24]. Genotype and allele fre-
ACE genotypes did not influence the renal survivalquencies were extracted, and the ORs were calculated.
(Fig. 1). Multivariate analysis by Cox’s proportional haz-The statistical analyses were performed on the distribu-
ard model revealed that only serum creatinine (P tion of the DD  ID versus II genotype. To test for the
0.0007; hazard ratio (HR) 3.4; 95% CI, 1.7 to 7), severestability of the results, two additional approaches were
proteinuria (P 
 0.0001; HR 8.4; 95% CI, 3.3 to 21.2),performed on the distribution of the DD versus II  ID
and severe histological grade (P  0.02; HR  4.2; 95%genotypes and on allele frequency. The total OR and
CI, 1.26 to 14.4) at the time of renal biopsy were indepen-95% confidence interval (CI) were calculated using
Peto’s odds ratio. Heterogeneity of the studies was as- dently predictive of poor outcome.
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Table 1. Distribution of the ACE genotypes and alleles, ent in the studies of Tanaka et al [22] and Hunley et
expressed in percentages, in our IgAN patient population
al [25].at the time of renal biopsy
Follow-up. In our study, only 26 IgAN patients had
Genotypes Alleles
N a minimal follow-up of one year; the total mean follow-
of cases DD ID II D I up was 5.3  5.2 years. In the other studies the mean
Age follow-up ranged from 2.4 years [21] to more than ten
18 years 49 33 50 17 58 42 years [20].
18 years 198 39 44 17 61 39
Methods. We used the Genomix kit (Trieste, Italy).Gender
Males 176 40 41 19 61 39 The Quiagen kit (Germany) was used in one study [20],
Females 71 34 55 11 61 39 Genomix kit in two studies [21, 22], and the Salting out
Normotensive 144 43 42 15 64 36
method in two studies [24, 26]. To minimize the mistypingHypertensive 103 31 50 19 56 44
Proteinuria of the ID genotype as DD, dimethyl sulfoxide (DMSO;
1 g/24 h 156 39 45 16 61 39 5%, vol:vol) was added to the PCR reaction in five stud-
1–3 g/24 h 72 37 42 21 58 42
ies [21–24, 26], while two PCR reactions were used in3 g/24 h 19 37 58 5 66 34
Serum creatinine three studies [20, 25, 26]. Our study used two PCR reac-
1.5 mg/dL 210 38 46 16 61 39 tions for improving the accuracy of genotyping.
1.5 mg/dL 37 39 39 22 58 42
Genotype frequency. The study patient populationsCCr (Cockcroft)
70 mL/min 188 37 49 14 61 39 were in Hardy-Weinberg equilibrium in all studies. How-

70 mL/min 59 43 33 24 59 41 ever, Yoshida et al found a significant difference in the
Renal lesions
subgroup of patients with deteriorating renal functionMild (G1–G2) 90 35 49 16 59 41
Moderate (G3) 92 42 45 13 64 36 [20] and Schmidt et al found the same thing in those with
Severe (G4–G5) 65 38 39 23 58 42 ESRD [24]. In our study, the distribution of genotype
frequencies was identical to that of the other Caucasian
studies [23, 24, 26]. We did not find a significant differ-
ence in our patients and controls (2  0.38, P  0.83).
Epidemiological analysis The mean frequency of DD, ID, and II genotypes in the
IgAN patient population was significantly different fromThe distribution of ACE I\D genotype and alleles in
that of the control population in Asian patients (IgANour study and in seven retrieved articles are reported in
DD  0.20, ID  0.40, II  0.40; control DD  0.11,Table 2.
ID  0.46, II  0.43; 2  6.6; P  0.04) but not inNumber of patients and controls. Our study enrolled
Caucasians (IgAN DD  0.37, ID  0.44, II  0.19;247 IgAN patients and 205 controls, matched for age
control DD  0.34, ID  0.48, II  0.18; 2  3.87;and gender. Smaller sample sizes of IgAN patients and
P  0.14).controls were used for the study of ACE gene polymor-
Allele frequency. In our study, the allele frequencyphism by all investigators [20–23, 25], except for Schmidt
was identical to that of other Caucasian studies, andet al [24] and Pei et al [26].
there was no significant difference between the IgANRace. In our study, Caucasian patients and controls
patients and controls (2  0.27; P  0.59). The meanwere from Puglia region of South Italy, which has four
distribution of D and I allele frequency in IgAN patientsmillion inhabitants. In four studies in which Caucasians
was not significantly different from that of normal popu-were included, patients came from Scotland [23]; Ger-
lation either in Asians (D  0.34, I  0.66 vs. D  0.39,many, Northern Italy, Austria and Australia [24]; Ala-
I  0.61; 2  2.3; P  0.12) or Caucasians (D  0.58,
bama (USA) [25]; and Canada [26]. Three studies in-
I  0.42 vs. D  0.59, I  0.41; 2  0.28; P  0.6).
cluded Asian patients from Japan [20–22].
Gender. In our study, the number of male patients Meta-analysis
was higher than that of female patients with a ratio of The current study plus seven articles [20–26] that satis-
2.4 to 1, resembling the disease ratio. In three studies, fied the specific criteria listed in the statistical analysis
the number of male patients was higher than that of section of this article were chosen for the meta-analysis.
female patients [20, 22, 24–26]. In Yorioka et al’s study, The mean D allele frequency (0.34) was lower than that
the number of males was lower than females [21]. Three of the I allele (0.66) in the normal Japanese population
studies reported no data on control group gender [22, compared with the Caucasian population (D  0.58; I 
23, 25]. 0.42; Table 2). Therefore, the Japanese and Caucasian
Age. The mean age of our patients was 30  12 years population studies were analyzed separately. In total,
(range 5–66 years), and 48 of them were younger than the Asian studies comprised 198 IgAN patients and 220
18 years of age. In the other studies, only adult patients controls, whereas Caucasian studies included 719 IgAN
patients and 637 controls.were enrolled. Children, both boys and girls, were pres-
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Fig. 1. Renal survival in our IgAN patients
with the DD (17 events; solid line), ID (19
events; dashed line), and II (10 events; dotted
line) genotypes. Log rank test, P  0.48.
Table 2. Epidemiology and distribution of the ACE I/D genotype and allele in IgAN patients and controls enrolled in individual studies
Demographics Genotypes % Alleles %
Controls Age Follow-up Controls IgAN Controls IgAN
Authors [Ref] N N DD ID II DD ID II D I D Iyears
Yoshida et al [20] 46 53 38.52.1 10 7 52 41 30 32 38 33 67 46 54
Yorioka et al [21] 103 48 33.512 2.41.5 10 46 44 17 27 56 33 67 30 70
Tanaka et al [22] 71 97 11.70.5 ND 13 49 38 16 49 35 37 63 40 60
Harden et al [23] 98 100 14–79 ND 40 43 17 40 41 19 61 39 60 40
Schmidt et al [24] 234 204 4513.5 5 33 50 17 38 39 22 58 42 59 41
Hunley et al [25] ND 64 6–83 6.80.6 ND ND ND 14 59 27 ND ND 44 56
Pei et al [26] 100 168 4714 6.14.7 30 49 21 33 48 19 60 40 57 43
Present study 205 247 3012 5.3 35 47 18 38 45 17 59 41 61 39
Ethnicity was divided into two populations: Asian studies [20–22] and Caucasian studies [23–26]. The populations were in Hardy-Weinberg equilibrium in all
studies, except for those of Yoshida et al and Schmidt et al, that observed a significant difference respectively in the subgroup of patients with deteriorating renal
function (P 
 0.05) and in those with end-stage renal disease (P  0.04). ND is not described.
Results of meta-analysis in the development of IgAN [20-24, 26] because the control group data were not re-
ported in Hunley et al’s study [25]. The total OR valuesand in the progression of renal disease are reported in
Figures 2 and 3. A pooled estimate was performed when were 0.95 (95% CI, 0.64 to 1.42) and 0.93 (95% CI, 0.71
to 1.23), respectively.the homogeneity of the studies was confirmed by the
Breslow-Day 2 test (P not significant). Figure 2 shows Two additional approaches were used to investigate
to what extent the D allele influenced the onset of thethe meta-analysis of the ACE genotype polymorphism
in IgAN patients compared to controls, evaluating the disease, by changing the classification of the exposure
variable. Three different analyses are reported in TableORs of the presence of ACE D allele (DD  ID versus
II genotype). Only six selected studies were included 3: first, comparison of the DD  ID versus II genotype;
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Fig. 2. Association between ACE I/D poly-
morphism (ACE DD  ID versus II) and
IgA nephropathy. Odds ratio between IgAN
patients and controls are reported. OR with
95% confidence intervals (CI) for each study
together with the pooled estimate are shown.
The solid vertical line shows an OR of 1.
Fig. 3. Association of ACE gene polymor-
phisms (DD  ID vs. II) and progression of
renal damage in IgAN patients. Odds ratio
between IgAN patients with and without dete-
riorating renal function are reported.
second, comparison of the DD versus ID II genotypes; did not reach a statistical significance. At the same time
and third, the D versus I allele frequency. It is evident the significant OR value estimated in our study suggests
that an increased risk with the homozygous DD genotype a paradoxical protective effect of the D allele, but the
(96%) was present among Asians (OR, 1.96, 95% CI, meta-analysis of Caucasian population studies demon-
1.13 to 3.41). In contrast, a very small risk without statisti- strated a total OR value of 1.12 (95% CI, 0.67 to 1.88).
cal significance (17%) of IgAN was evident among Cau- This indicates that there is no relationship between the
casians (OR, 1.17, 95% CI, 0.94 to 1.46). D allele and the deterioration of renal function.
Figure 3 shows the meta-analysis of the association be-
tween ACE D/I genotype polymorphism and deteriorat-
DISCUSSIONing renal function in IgAN patients. The analysis in Asian
Our study, which includes a cohort of patients withpopulation was limited to one study [20] because no data
biopsy-proven IgAN enrolled in a restricted area with awere available in the other studies. Even though the in-
sufficient follow-up, shows no influence of the ACE I/Dfluence of the D allele in deteriorating renal function was
reported in this Japanese study [20], the OR value of 2.26 gene polymorphism (genotype distribution and allele fre-
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Table 3. Comparison of the association between IgAN and ACE Asians because the frequency of this genotype is notably
gene polymorphisms based on three different analyses
low in some populations (Australian Aboriginal, Chi-
Odds Homogeneity nese, and Japanese 0.5%, 6%, and 18%, respectively),
Group ratio 95% CI of resultsa whereas it is very high in Caucasians. Most likely, sto-
Asian IgAN patients chastic or epistatic factors enhanced by small breeding
DD ID versus II 0.95 0.64–1.42 Yes
population sizes, limited gene pool and geographical iso-DD versus ID II 1.96 1.13–3.14 Yes
D vs. I allele frequency 1.18 0.88–1.57 Yes lation play a major role in this population’s loss of genetic
Caucasian IgAN patients polymorphism. Perhaps the I and D alleles in Japan do
DD ID versus II 0.94 0.71–1.23 Yes
not bear exactly the same haplotype of the ACE geneDD versus ID II 1.17 0.94–1.46 Yes
D vs. I allele frequency 1.06 0.91–1.23 Yes as they do in Europe and are associated with some other
difference in the expression of this gene. The enrollmenta 2 test by Breslow-Day
of cases and controls of a restricted area in our study
reduces the likelihood of selection bias and the effects
of confounding factors. In addition, the finding of almost
quency) on the development of the IgAN and on the identical genotype and allele frequencies among a large
progression of the renal damage. population of controls and patients matched for number,
Some investigators observed that the frequency of DD age, and gender give us considerable confidence in the
genotype was significantly higher in those patients with reliability of our data.
progressive deterioration of the renal function, and they Our meta-analysis supports the notion that develop-
concluded that the DD genotype was a genetic marker ment of IgAN is not associated with the presence of the
of poor prognosis either in Asian [20, 21] or Caucasian D allele in the Asian and Caucasian populations. Only
patients [23, 25]. Others, at least for Caucasians, did not the homozygous DD genotype could be associated with
confirm these data [24, 26]. Our study, performed in a the development of IgAN (1.96 of risk) in the Asian
cohort of ethnically homogeneous South Italy Caucasian population. The risk for the progression of renal damage
patients, shows that the frequency of the DD genotype was reported only in Asian patients [20]. However, given
and the D allele was not significantly increased in pa- the small sample size of enrolled patients, this finding
tients with IgAN and in those with deteriorating renal needs to be confirmed by studying a larger cohort of
function during the post-renal biopsy follow-up. Asian IgAN patients. In fact, the pooled estimate in
Hunley et al demonstrated that when IgAN patients Caucasian patients does not confirm the poor prognostic
were analyzed separately for their renal function, the role of the DD genotype and D allele. This consideration
DD genotype as well as the D allele was strictly associ- suggests that association studies, performed in a well-
ated with the progressive decline of the renal function. designed manner, should be done using large population
The DD patients with normal renal function, no hyper- samples of patients and controls. Recent studies docu-
tension, and proteinuria at the time of renal biopsy had menting an increased risk of left ventricular hypertrophy
a 7.5 times higher risk to develop progressive deteriora- in subjects with the DD genotype [36, 37] and of ne-
tion of renal function than those who did not have this phropathy in DD insulin-dependent diabetes mellitus
genotype [25]. They concluded that the DD genotype is [38–40] were not confirmed when large population stud-
an independent risk factor for renal progression because ies were done or when pooled data analysis was applied
D homozygous patients progressed independently of [33, 41–44]. Recently, Japanese investigators reconsid-
proteinuria and hypertension, which are two important ered the effect of the ACE I/D gene in the progression
risk factors responsible for poor renal prognosis. In an of renal damage in IgAN patients and they did not find
effort to replicate these findings, we divided our large a significant correlation [45].
sample of IgAN patients with normal renal function at An important purpose of a meta-analysis is to help
the time of renal biopsy into two groups, nonprogressors direct future research. Our findings suggest that addi-
and progressors to renal insufficiency, and found no asso- tional research into the association of genetic variability
ciation with DD genotype. There are several explana- of the ACE and other genes and IgAN is warranted in
tions for the discrepancy between our findings and the genetically homogeneous populations. For IgAN, which
earlier observations. Previously published studies were is a multifactorial disease with several major susceptibil-
limited by their heterogeneously selected populations ity loci, the sample size required to replicate a linkage
[20–23, 25]. In addition, it has been pointed out that or association study to a specific locus should be larger
there is considerable variability in the frequency of the than in previous studies. For this reason, it is useful to
DD genotype among so-called controls in smaller studies organize a multicenter collaborative study to assemble
and among populations [33–35]. In fact, we cannot ex- a large cohort of patients. The number of cases associat-
clude the possibility that DD genotype can influence ing an allele with a particular phenotype must be large
enough to be convincing.IgAN development and progression of renal damage in
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